Impact of nirsevimab on admission to a Spanish pediatric intensive care unit because of RSV bronchiolitis: Unicentric observational study from 2017 to 2024
- 28 August 2024
- journal article
- letter
- Published by Wiley in Pediatric Pulmonology
- Vol. 59 (12) , 3783-3786
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024MMWR. Morbidity and Mortality Weekly Report, 2024
- First RSV epidemic with nirsevimab. Older children than previous epidemics, even when hospitalizedJournal of Medical Virology, 2024
- Respiratory Syncytial Virus (RSV) Burden in Infants in the Kingdom of Saudi Arabia and the Impact of All-Infant RSV Protection: A Modeling StudyAdvances in Therapy, 2024
- Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024Eurosurveillance, 2024
- Nirsevimab para la prevención de la enfermedad por virus respiratorio sincitial en niños. Posicionamiento de la Sociedad Española de Infectología PediátricaAnales de Pediatría, 2023
- Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trialsNature Communications, 2023